Article in Infection and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Eddy Sánchez-León *Michael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0003-1571-2361
Kabir Bhalla *Michael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0001-7645-3725
Victoria FrenchDepartment of Chemical and Biological Engineering, BioProducts Institute, University of British Columbia, Vancouver, BC, Canada.
Polina BeskrovnayaDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada.
Shweta ParmarDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada.
Guanggan HuMichael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada.
Melissa LagaceMichael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada.
Sophie ThanasackMichael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada.
E Johan FosterDepartment of Chemical and Biological Engineering, BioProducts Institute, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0002-4103-8510
Elitza I TochevaDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0002-4869-8319
James W KronstadMichael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0003-4240-6976
Funding
Comparative and functional genomics of C. neoformansR01AI053721 · NIAID · UNIVERSITY OF BRITISH COLUMBIA · PI KRONSTAD, JAMES W · 2003 to 2024
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
The AP-1 adaptor complex is required for cell surface modifications and the survival of · full record | Socratic